摘要:
The invention concerns the compounds 8,9-Diethoxy-2-methyl-6- [4(p-toluenesulfonamido)phenyl] -1,2,3,4,4a,10b-hexahydrobenzo[c] [1,6]naphthyridine and 9-Ethoxy-8-methoxy-2- methyl-6-[4-(p-toluenesulfonamido) phenyl]-1,2,3,4,4a,10b-hexahydrobenzo [c][1,6]naphthyridine and their therapeutic application.
摘要:
Disclosed are new compounds of general formula (I), in which one of the substituents R1 and R2 is a methoxy, difluoromethoxy or ethoxy group and the other is a C4-C7 cycloalkoxy or C3-C7 cycloalkylmethoxy group, as well as the salts formed by these compounds with bases. The compounds are suitable for use as active ingredients in bronchospasmolytics.
摘要:
Composition for the treatment of infant or adult respiratory distress syndrome (IRDS and ARDS) contains N-(3,5-dichloropyrid-4-yl)-3- cyclopropylmethoxy-4- difluoromethoxybenzamide (II) (and/or its salts) and a lung surfactant.
摘要:
Novel compositions are disclosed for the treatment of IRDS and ARDS, containing at least one glucocorticosteroid and a pulmonary surfactant. The duration of treatment and the mortality associated with these syndromes can be significantly reduced with the proposed novel compositions.
摘要:
Des composés de formule (I), où les substituants ont les significations mentionnées dans la description, sont de nouveaux bronchodilateurs efficaces.
摘要:
The invention relates to the combined use of the PDE4 inhibitor N- (3,5-dichloropyrid-4-yl)- 3-cyclopropylmethoxy- 4-difluoromethoxybenzamide, its pharmacologically tolerable salts or its N- oxide with a PDE3 inhibitor for the treatment of certain disease conditions such as, for example, acute or chronic obstructions of the bronchi.
摘要:
Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33- substituted phenyl or R34, R35, R36 and R37- substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-alkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs.
摘要:
Des composés ayant la formule générale (I), dans laquelle un des substituants R1 et R2 désigne méthoxyle, difluorométhoxyle ou éthoxyle et l'autre désigne cycloalcoxyle C4-C7 ou cycloalkylméthoxyle C3-C7, ainsi que leurs sels avec des bases, sont nouveaux et utiles comme principes actifs bronchospasmolytiques.
摘要:
Utilisation de télenzépine et de (+)télenzépine pour le traitement de maladies des bronches. (+)Télenzépine, son procédé de production et produits intermédiaires pour sa production.